Juan Carlos López-Talavera

Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients

Stephen Macfarlane, Timo Grimmer, Ken Teo, Terence J. O’Brien et autres

gb, de, au, us, Togo, pa, rs, ca, jp, cn, lb, fr (code pays fourni par la source)

WED-220 BOS-580, a long-acting FGF-21 analogue, treatment shows beneficial changes in the circulating lipidome and improves MASEF score in patients with phenotypic metabolic dysfunction-associated steatohepatitis in a phase 2a randomized, placebo-controlled, 12-week study

Gerard Bain, Alicia Clawson, Juan Carlos López-Talavera, Tatjana Odrljin

Corrigendum to: “Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results” [JHEP Reports 5 (2019) 101041]

Annieke C.G. van Baar, Ulrich Beuers, Kari E. Wong, Rehan Haidry et autres

nl, us, gb, it, be, br (code pays fourni par la source)

IMPROVEMENTS IN INSULIN SENSITIVITY SEEN IN PATIENTS WITH TYPE 2 DIABETES AFTER REVITA® DMR IS ASSOCIATED WITH A DECREASE IN GLUCAGON, GLUCOSE, AND GIP AFTER A MIXED MEAL TOLERANCE TEST

Celine Busch, Suzanne Meiring, Annieke C. Van Baar, Kelly White et autres

Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study)

Annieke C.G. van Baar, Jacques Devière, David Hopkins, Laurent Crenier et autres

nl, be, gb, br, it, us (code pays fourni par la source)

A Gut-Centric Model of Metabolic Homeostasis

Harith Rajagopalan, Juan Carlos López-Talavera, David C. Klonoff, Alan D. Cherrington

us (code pays fourni par la source)

Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial

Geltrude Mingrone, Annieke C. Van Baar, Jacques Devière, David Hopkins et autres

it, gb, nl, be, jp, au, br, us (code pays fourni par la source)

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

Michael Fried, Juan Carlos López-Talavera, Heiner Wedemeyer, Roger Trinh et autres

us (code pays fourni par la source)

121-LB: Durable Glycemic Improvements after Duodenal Mucosal Resurfacing (DMR) in Patients with Type 2 Diabetes (T2D): 48-Week Results from the REVITA-2 European Cohort

Geltrude Mingrone, David Hopkins, Guruprasad P. Aithal, Guido Costamagna et autres

OR30-07 Mixed Meal Tolerance Test (MMTT) Results from Revita-2, the First Randomized, Sham-Controlled, Double-Blind, Prospective, Multicenter Study of Duodenal Mucosal Resurfacing (DMR) Safety and Efficacy in Patients with Sub-Optimally Controlled Type 2 Diabetes (T2D)

David Hopkins, Geltrude Mingrone, Guruprasad P. Aithal, Vijeta Bhambhani et autres

gb, it, us, be, nl (code pays fourni par la source)

Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results

Annieke C.G. van Baar, Ulrich Beuers, Kari E. Wong, Rehan Haidry et autres

nl, us, gb, it, be, br (code pays fourni par la source)

Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir +/-Ribavirin in Patients Receiving Concomitant Acid-Reducing Agents in Phase 3 Trials

Mitchell Shiffman, Vinod K. Rustgi, Michael Bennett, Xavier Forns et autres

us, es, fr (code pays fourni par la source)